April 12, 2021 in Kineta Press Release

Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021

Kineta Presents New Preclinical Data on its Lead VISTA Antagonist Antibody at the AACR Annual Meeting 2021

Seattle, WA — (April 12, 2021) Kineta, Inc., a clinical stage biotechnology company focused on the development of novel immunotherapies in oncology, announced today the presentation of new preclinical data on its VISTA antagonist antibody at the American Association for Cancer Research (AACR) Annual Meeting 2021.  Thierry Guillaudeux, PhD, Senior Vice President Immuno-oncology at Kineta, presented a poster detailing new preclinical data on the company’s lead anti-VISTA antibody.

Key results with Kineta’s anti-VISTA lead antibody include the following:

  • Highly specific VISTA binding
  • Activates monocytes and this activation is NK cell dependent
  • Reverses MDSC suppression of T cells
  • Induces strong anti-tumor response as a single agent or in combo-therapies with anti-PD1 in different hard to treat tumor models

“Our lead anti-VISTA antibody has demonstrated exceptional preclinical performance which will enable Kineta to develop a differentiated immunotherapy with a new mechanism of action compared to the current T cell focus immunotherapies” said Shawn Iadonato, PhD, Chief Executive Officer at Kineta. “We are excited to advance IND enabling studies and enter the clinic in early 2022.”

VISTA is a key driver of the immunosuppressive tumor microenvironment (TME) and is overexpressed on myeloid-derived suppressor cells (MDSC) and regulatory T cells (Tregs). It is a critical myeloid cell immune-checkpoint, and VISTA blockade can reprogram suppressive myeloid cells and reactivate antitumor immune function. Blocking VISTA activates an immune cell cascade that increases T cell effector functions to drive an efficient anti-tumor response. Preclinical studies have demonstrated single agent anti-VISTA activity but also demonstrate that targeting VISTA in combination with PD-1, PD-L1 or CTLA-4 can significantly improve the efficacy of those checkpoint inhibitors.

Presentation Details:

Title:                            A fully human anti-vista antibody as a promising therapy against poorly immunogenic tumors
Session Type:              E-Poster Session
Session Title:               Immune Checkpoints
Poster Number:          1637
Presenter:                    Thierry Guillaudeux, PhD

Click on the link below to take you to the Kineta website where you can view the presentation:

VISTA Publications – Kineta VISTA Presentation at AACR


Kineta, Inc. is a clinical stage biotechnology company committed to developing disruptive life science technologies that address unmet patient needs.  We have leveraged our expertise in immunology and innate immunity to advance a focused pipeline of investigational drugs in oncology and neuroscience.  We actively collaborate with a broad array of private, government and industry partners to advance our innovative products.  For more information on Kineta visit our website, www.kinetabio.com, follow us on Twitter at @kinetabio, LinkedIn and Like us on facebook.com/KinetaBio.

NOTICE: This document contains certain forward-looking statements, including without limitation statements regarding Kineta’s and its affiliates’ plans for pre-clinical and clinical studies, regulatory filings, investor returns and anticipated drug effects in human subjects. You are cautioned that such forward-looking statements are not guarantees of future performance and involve risks and uncertainties inherent in Kineta’s and its subsidiaries’ businesses which could significantly affect expected results, including without limitation progress of drug development, ability to raise capital to fund drug development, clinical testing and regulatory approval, developments in raw material and personnel costs, and legislative, fiscal, and other regulatory measures. All forward-looking statements are qualified in their entirety by this cautionary statement, and neither Kineta nor its affiliates undertake any obligation to revise or update any forward-looking statement to reflect events or circumstances after the issuance of this press release.

Jacques Bouchy
(206) 378-0400